Quick Answer
Denali Therapeutics Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Denali Therapeutics Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $330.53M | +204.7% |
| 2022 | $108.46M | +122.9% |
| 2021 | $48.66M | -85.5% |
| 2020 | $335.66M | +1158.2% |
| 2019 | $26.68M | -79.3% |
| 2018 | $129.16M | — |
| 2017 | $0.00 | — |
| 2016 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $1.27M | -64.4% | -99.6% |
| June 30, 2023 | $294.12M | +460.4% | +737.0% |
| March 31, 2023 | $35.14M | -16.6% | +887.4% |
| September 30, 2022 | $3.56M | -32.7% | -93.2% |
| June 30, 2022 | $52.48M | +128.8% | +24.5% |
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: